+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 37 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating the effects of nivolumab combined with blinatumomab compared to blinatumomab alone in patients with first relapse B-cell acute lymphoblastic leukemia B-ALL, including those with Down syndrome. This phase II trial aims to assess event-free survival and safety in children and young adults aged 1 to under 31 years. The study also explores remission rates and adverse events related to these treatments. Participants receive different combinations of blinatumomab, nivolumab, dexamethasone, methotrexate, and other chemotherapy drugs depending on their assigned group or arm. Treatment cycles generally last 36 to 37 days and may repeat up to two cycles if no disease progression or unacceptable toxicity occurs. Additional therapies like radiation and intrathecal chemotherapy are given based on disease characteristics. Down syndrome patients have a specific treatment arm with tailored medication schedules. Throughout the study, participants undergo lumbar punctures, bone marrow biopsies and aspirations, and collection of blood, urine, and cerebrospinal fluid for monitoring. Follow-up visits occur every three months for one year after treatment completion to assess outcomes such as minimal residual disease negative remission and event-free survival. Safety and tolerability are closely monitored during therapy and follow-up.

Age: 1Year - 30YearsAll GendersPhase 2
227 locations
P

Actively Recruiting

Researchers are evaluating how well active surveillance helps doctors monitor patients with low-risk germ cell tumors after tumor removal. The trial also compares two chemotherapy regimenscarboplatin-based and cisplatin-basedin treating pediatric, adolescent, and young adult patients with standard risk germ cell tumors. This phase III study aims to maintain high survival rates and assess event-free survival, hearing outcomes, body composition effects, and tumor marker correlations. The study includes patients with low-risk stage I germ cell tumors who undergo observation and may transfer to standard risk treatment arms if the tumor recurs. Participants with standard risk non-seminomatous germ cell tumors are randomly assigned to one of four chemotherapy regimens involving bleomycin, etoposide, carboplatin, or cisplatin. Treatments are given intravenously in cycles every 21 days, with up to 3 or 4 cycles depending on the arm and risk group. Throughout the trial, patients undergo imaging scans, blood sample collections, tumor biopsies, and pulmonary function tests to monitor response and side effects. Participants are followed for up to 10 years after treatment completion, with regular visits every 2 months for the first year, then every 3 to 6 months for the next two years, and less frequently thereafter. The study tracks overall survival, event-free survival, hearing loss, patient-reported hearing outcomes, lean body mass, and tumor marker declines. Safety is monitored with tests including audiometry and pulmonary function, and patient questionnaires assess effects such as tinnitus and neuropathy. This long-term follow-up helps evaluate treatment impact and late effects.

All AgesAll GendersPhase 3
629 locations
R

Actively Recruiting

Researchers are evaluating the use of olaparib, a PARP inhibitor, as a maintenance treatment following surgery and chemotherapy in patients with pancreatic cancer that has been surgically removed and who have a pathogenic mutation in BRCA1, BRCA2, or PALB2. This phase II randomized trial aims to determine if adding olaparib improves relapse-free survival compared to placebo. The study also explores overall survival and treatment effects based on genetic mutation types and prior chemotherapy regimens. Participants are randomly assigned to receive either olaparib or a placebo taken orally twice daily in 28-day cycles for up to 12 cycles, provided there is no disease progression or unacceptable side effects. Throughout the study, patients undergo CT or MRI scans and have blood samples collected regularly. After completing treatment, patients are followed for up to 10 years with scheduled visits at 30 days post-treatment, every 4 months during the first year, and every 6 months for years 2 through 10. During the trial, participants are closely monitored through imaging and blood tests to assess disease recurrence and overall survival. The primary outcome measures relapse-free survival from randomization up to 44 months, while secondary outcomes include long-term survival and comparisons of treatment effects based on mutation type and chemotherapy received. Safety and disease status are assessed regularly to track treatment impact and progression over an extended follow-up period.

Age: 18Years +All GendersPhase 2
456 locations
E

Actively Recruiting

Researchers are studying adults newly diagnosed with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancers who are starting systemic cancer treatments such as chemotherapy or immune checkpoint inhibitors. The purpose is to understand how cannabis and cannabinoid use relates to cancer-related symptoms over one year. This observational study enrolls 2000 participants to explore these associations in community oncology settings. Participants do not receive any experimental treatments but complete surveys and have their medical records reviewed. Assessments occur monthly for up to 12 months, capturing cannabis use, perceived benefits and harms, and adverse effects alongside symptom tracking. There is an optional sub-study for some participants receiving immune checkpoint inhibitors at specific cancer centers. During the study, participants complete monthly surveys either online at home, in clinic, or other locations, and their medical records are reviewed for treatment and symptom information. Researchers measure cancer-related symptoms and cannabis use patterns over time. The study monitors participants for up to one year to evaluate symptom changes and cannabis-related effects, with no intervention administered by the study team.

Age: 18Years +All Genders
491 locations
B

Actively Recruiting

Healthy Volunteer

Researchers are collecting blood and tissue samples from people with and without cancer to help develop and evaluate tests for early cancer detection. This observational study aims to create a blinded reference set of blood samples from cancer and non-cancer patients to validate new blood-based multi-cancer early detection tests. The study also evaluates test performance at the time of initial cancer diagnosis by tumor type and clinical stage. Participants complete a questionnaire at the start of the study and provide blood samples at registration and again 12 months later. Patients diagnosed with cancer may also provide tissue samples at these same times. The study collects these biospecimens to help researchers study and validate early cancer detection assays in the laboratory. During the study, participants are monitored with follow-up at one year after enrollment. Researchers assess the quality and usefulness of the collected blood samples as a blinded reference set for cancer detection tests. The main outcome is the provision of these samples over up to one year, with additional evaluation of test performance by tumor type and stage. Participants involvement includes questionnaires, blood draws, and possible tissue sample collection, with no treatment interventions involved.

Age: 40Years - 75YearsAll Genders
751 locations
N

Actively Recruiting

Researchers are collecting biological samples and medical data from patients who experience serious side effects after receiving immunotherapy treatments for cancer. This observational study aims to build a national collection of these samples and data to help future research better predict, prevent, and manage these immune-related adverse events, rare infections, or rapid tumor growth. Participants provide tissue, blood, and optionally stool samples if they experience colitis, shortly after confirmation of a severe immune-related side effect and again one month later. Their medical records will be reviewed for up to one year to gather detailed clinical information. This study does not involve administering treatments but focuses on collecting data and samples from those already treated with immuno-oncology therapies. During the study, participants undergo sample collections at registration and one month later. Researchers will review medical records over a year to monitor health outcomes and side effects. The main measurement is establishing the biorepository of samples and data for future studies. Participation duration can last up to one year with periodic assessments based on medical record review and sample collection.

All AgesAll Genders
630 locations
E

Actively Recruiting

Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.

Age: 18Years +All GendersPhase 2Phase 3
1085 locations
P

Actively Recruiting

Researchers are evaluating combinations of targeted drugs in people with advanced non-small cell lung cancer that has spread and shows specific changes in the EGFR and MET genes. This phase II Lung-MAP trial focuses on patients whose cancer has progressed after treatment with osimertinib and aims to compare the effectiveness of combining capmatinib, osimertinib, and ramucirumab. The study also investigates safety, response rates, and survival outcomes while collecting biological samples for further analysis. Participants are randomly assigned to one of two groups. One group receives capmatinib and osimertinib as oral medications plus ramucirumab given intravenously, while the other group receives only capmatinib and osimertinib orally. During the trial, patients undergo regular CT or MRI scans and blood sample collections to monitor their disease and treatment effects. The study includes detailed assessments of tumor responses and side effects over time. Throughout the trial, participants will have scans and blood tests at scheduled intervals to assess disease progression and treatment impact. Researchers will monitor progression-free survival as the main outcome, along with response duration and toxicity. Blood samples are also collected to study circulating tumor DNA. The study continues up to three years, with ongoing safety and efficacy evaluations. Participants must meet specific health criteria and provide informed consent before joining.

Age: 18Years +All GendersPhase 2
454 locations
P

Actively Recruiting

Researchers are evaluating whether adding surgery to remove the kidney cytoreductive nephrectomy improves overall survival compared to immunotherapy-based drug combinations alone in patients with metastatic kidney cancer. This phase III trial focuses on patients with newly diagnosed metastatic renal cell carcinoma, exploring the effects of combining surgery with immunotherapies such as nivolumab, ipilimumab, pembrolizumab, and avelumab, along with axitinib, which may help slow tumor growth. Participants initially receive one of three standard immune checkpoint inhibitor-based regimens before randomization. After 10 to 14 weeks, eligible patients are randomly assigned to continue systemic immunotherapy with or without surgery to remove the kidney. Surgery may be performed within 8 weeks after randomization and can be done using laparoscopic, open, or robotic methods. Immunotherapies continue alongside axitinib unless surgery is planned, in which case axitinib is paused at least 24 hours before surgery. Throughout the study, participants undergo scans, physical exams, and laboratory tests to monitor tumor response and overall health. After treatment, patients are followed up every 3 months for the first year, then every 6 months for up to 3 years, and annually up to 7 years from randomization. The main measurement is overall survival, with additional assessments including tumor response, progression-free survival, treatment complications, and changes in tumor size at week 12. Specimens may be collected for future research.

Age: 18Years +All GendersPhase 3
387 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the impact of the Cost Communication and Financial Navigation CostCOM intervention on adherence to cancer care and financial burden among patients with malignant solid tumors. This study compares the effects of enhanced usual care and the CostCOM program, which offers financial counseling and resource connections to reduce financial barriers and stress. The study aims to assess cost-related non-adherence, financial hardship, worry, quality of life, and satisfaction with care over 12 months. Participants are randomly assigned to one of two groups one group receives a brochure about financial navigation services, while the other group receives usual financial care plus CostCOM counseling sessions lasting about one hour within 30 days of enrollment and again at 3, 6, and 12 months. Non-patient participants involved in the study complete surveys and participate in in-depth interviews between 15 and 39 months after the first patient enrollment. During the study, patients complete surveys at baseline and at 3, 6, and 12 months to report on financial worry, quality of life, and satisfaction with care. Researchers track adherence to cancer treatment and financial outcomes over one year. Non-patient participants contribute by completing surveys and interviews to provide insights into the use and experience of the CostCOM intervention. The total participation time extends up to 12 months for patients and up to 39 months for non-patient participants.

All AgesAll GendersPhase Not Applicable
391 locations

1-10 of 37

1